Press release
CytomX Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update
Company to host a conference call today, November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) --
About this update from Cytomx Therapeutics, Inc.
[{"type":"text","content":"Company to host a conference call today, November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT\nSOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today reported third quarter 2020 financial results and provided a business update.\n\n \n \n \n \n \n \n \n \n \n \n \n * Denotes subject who is considered to be on treatment, as no End of Treatment date is in the database.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n aNSC = non–small cell lung cancer (adenocarcinoma), CRC = colorectal cancer, HCC = hepatocellular carcinoma, HN = head and neck squamous cell carcinoma, MPM = malignant pleural mesothelioma, PAC = pancreatic cancer, PEC = perivascular epithelioid cell tumor, sNSC=non–small cell lung cancer (squamous cell carcinoma), TC = thyroid carcinoma. *Denotes subjects still on treatment.\n \n \n \n \n \n \n \n \n\n “As we approach the end of the year, the productivity of our R&D engine is evident with the growing breadth of our clinical pipeline, which is increasingly focused on previously undruggable targets. Between CytomX and our partners, there are now five Probody programs in the clinic, with four in Phase 2 studies, including CX-2029, for which we were excited to announce the treatment of the first patient in the expansion cohorts earlier today,” said Sean McCarthy, D.Phil., president, chief executive officer and chairman of CytomX Therapeutics. “So far this year, we have reported single agent anti-cancer activity for CX-072, CX-2009 and CX-2029, and we also are encouraged by the promising Phase 1 tolerability data reported by BMS for the anti-CTLA-4 Probody, BMS-986249. In addition, we continue to advance compelling preclinical candidates targeting EpCAM and EGFR-CD3 toward clinical development. Looking ahead to 2021, we believe we are well positioned for significant data updates from our robust clinical portfolio.” THIRD QUARTER BUSINESS HIGHLIGHTS AND RECENT DEVELOPMENTS Clinical Pipeline Progress: Advancing into Multiple Phase 2 Expansion Cohorts CX-2009: Phase 2 Expansion Studies in HER2 Negative Breast Cancer Subtypes in 2020 CytomX expects to initiate a redesigned, multi-arm Phase 2 study evaluating CX...